Medipost to conduct first clinical trial of stem cell therapy

Published: 2010-11-04 06:58:00

Updated: 2010-11-04 06:58:00

Medipost Co., Ltd., one of the nation’s leading bioengineering firms, said on November 2 that it will conduct its Phase I clinical trial of Neurostem, a placenta based embryonic stem cell, for treatment of Alzheimer’s dementia.

According to the company, embryonic stem cells have the potential ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK